Almost all patients with hypertrophic cardiomyopathy have some degree of diastolic dysfunction, which can be improved by medical therapy, septal alcohol ablation, and surgical myectomy.
Diastolic dysfunction is a ubiquitous feature of hypertrophic cardiomyopathy, and its quantification is important for identifying preclinical disease and assessing response to therapies.
ypertrophic cardiomyopathy (HCM) is a primary autosomal-dominant disorder of the myocardium caused by mutations in sarcomeric contractile proteins. 2] This is shown by the variability of the age of onset of clinical disease, degree and location of hypertrophy, and presence and site of intraventricular dynamic pressure gradients. Despite this heterogeneity, almost all patients with HCM have some degree of diastolic dysfunction. The presence of subtle changes in LV filling may even identify patients with preclinical disease without LV hypertrophy. Interventions such as medical therapy, septal alcohol ablation, and surgical myectomy improve symptoms by both reducing the left ventricular (LV) outflow tract gradients and improving diastolic function.
Rakowski et al. (Mon,) conducted a review in Hypertrophic Cardiomyopathy. Almost all patients with hypertrophic cardiomyopathy have some degree of diastolic dysfunction, which can be improved by medical therapy, septal alcohol ablation, and surgical myectomy.